AIRLINK 74.82 Increased By ▲ 0.53 (0.71%)
BOP 4.94 Decreased By ▼ -0.01 (-0.2%)
CNERGY 4.38 Increased By ▲ 0.01 (0.23%)
DFML 39.02 Increased By ▲ 0.22 (0.57%)
DGKC 85.35 Increased By ▲ 0.53 (0.62%)
FCCL 21.25 Increased By ▲ 0.04 (0.19%)
FFBL 34.00 Decreased By ▼ -0.12 (-0.35%)
FFL 9.70 No Change ▼ 0.00 (0%)
GGL 10.43 Increased By ▲ 0.01 (0.1%)
HBL 113.69 Increased By ▲ 0.69 (0.61%)
HUBC 136.95 Increased By ▲ 0.75 (0.55%)
HUMNL 11.90 No Change ▼ 0.00 (0%)
KEL 4.84 Increased By ▲ 0.13 (2.76%)
KOSM 4.47 Increased By ▲ 0.03 (0.68%)
MLCF 37.75 Increased By ▲ 0.10 (0.27%)
OGDC 138.60 Increased By ▲ 2.40 (1.76%)
PAEL 25.30 Increased By ▲ 0.20 (0.8%)
PIAA 20.45 Increased By ▲ 1.21 (6.29%)
PIBTL 6.63 Decreased By ▼ -0.08 (-1.19%)
PPL 122.55 Increased By ▲ 0.45 (0.37%)
PRL 26.80 Increased By ▲ 0.15 (0.56%)
PTC 13.91 Decreased By ▼ -0.02 (-0.14%)
SEARL 58.10 Increased By ▲ 0.88 (1.54%)
SNGP 67.24 Decreased By ▼ -0.36 (-0.53%)
SSGC 10.32 Increased By ▲ 0.07 (0.68%)
TELE 8.36 Decreased By ▼ -0.04 (-0.48%)
TPLP 11.14 Increased By ▲ 0.01 (0.09%)
TRG 63.45 Increased By ▲ 0.64 (1.02%)
UNITY 26.53 Increased By ▲ 0.03 (0.11%)
WTL 1.48 Increased By ▲ 0.13 (9.63%)
BR100 7,833 Increased By 23.2 (0.3%)
BR30 25,336 Increased By 186.3 (0.74%)
KSE100 75,103 Increased By 146.7 (0.2%)
KSE30 24,128 Increased By 44.8 (0.19%)

Swiss drugmaker Roche Holding AG plans to sell its 800-employee drug manufacturing plant in Vacaville, California, or it will shut the factory by 2029, according to e-mailed letters to workers seen by Reuters on Wednesday.

In a statement, Roche confirmed the divestiture plan for the site, which makes monoclonal antibodies from genetically modified living cells, but did not address the potential closing of the plant or its timeline.

The company said in the statement it does not expect to need the very large volumes of the medicines the plant provides, and large-scale production will be done in one of the company’s newer plants.

It also plans to focus on drugs targeting smaller patient populations moving forward and to draw on a range of biotechnology methods beyond monoclonal antibodies, it said, adding there would be no impact to operations or employees at this time.

Roche is under new leadership this year after CEO Thomas Schinecker took the helm and Teresa Graham became head of the pharmaceuticals division in March.

The Swiss group is under pressure to develop new treatments to offset the loss of billions in sales due to cheap biotech copies of its established cancer medicines Herceptin, Avastin and Rituxan, some of which are made in Vacaville.

GSK Pakistan recognised as ‘top employer’

It is also contending with dipping revenue for its COVID-19 therapies and tests.

The company said it is seeking a buyer that will continue to use the plant as an operating facility. If the company is unable to find a buyer, it will ramp down production and close the plant in 2028 to 2029, the emails said.

Roche acquired the plant more than a decade ago with its purchase of US biotech Genentech.

The plant makes drugs for cancer including Avastin and Herceptin, as well as Actemra for rheumatoid arthritis. During the pandemic, Roche collaborated with Regeneron Pharmaceuticals to increase supply of that drugmaker’s COVID-19 antibody treatment.

Roche manufactured the treatment at the Vacaville plant, which it sells outside the US under the brand name Ronapreve.

Comments

Comments are closed.